SeaStar Medical Completes Enrollment of SCD 005 Trial to Evaluate Safety of Selective Cytopheretic Device (SCD) in AKI as well as ARDS Patients with COVID-19
Findings from the study in patients with AKI and/or ARDS with COVID-19 infection are expected later this year DENVER, JUNE 17, 2021 — SeaStar Medical, a medical technology company delivering novel therapeutic solutions to improve organ function, announced today that the company has completed enrollment of the SCD 005 study to evaluate the safety of […]